About Aldo-keto reductase family 1 member C4
Aldo-keto reductase family 1 member C4 (AKR1C4) is a protein
from Homo sapiens identified by UniProt accession
P17516, 323 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member C4 |
| UniProt accession | P17516 |
| Gene | AKR1C4 |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (110)
Diseases linked to this target (Open Targets).
- sex hormone-binding globulin measurement · score 0.44
- triglyceride measurement · score 0.44
- alkaline phosphatase measurement · score 0.41
- testosterone measurement · score 0.40
- hemoglobin measurement · score 0.40
- bilirubin measurement · score 0.37
- apolipoprotein A 1 measurement · score 0.37
- serum gamma-glutamyl transferase measurement · score 0.36
- total cholesterol measurement · score 0.36
- lymphocyte count · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P17516-F1 | alphafold | PREDICTED | 96.90 | — |
Amino-acid sequence (323 residues)
MDPKYQRVEL NDGHFMPVLG FGTYAPPEVP RNRAVEVTKL AIEAGFRHID SAYLYNNEEQ VGLAIRSKIA DGSVKREDIF YTSKLWCTFF QPQMVQPALE SSLKKLQLDY VDLYLLHFPM ALKPGETPLP KDENGKVIFD TVDLSATWEV MEKCKDAGLA KSIGVSNFNC RQLEMILNKP GLKYKPVCNQ VECHPYLNQS KLLDFCKSKD IVLVAHSALG TQRHKLWVDP NSPVLLEDPV LCALAKKHKQ TPALIALRYQ LQRGVVVLAK SYNEQRIREN IQVFEFQLTS EDMKVLDGLN RNYRYVVMDF LMDHPDYPFS DEY
Explore Aldo-keto reductase family 1 member C4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets